From basic research to clinical development of MEK1/2 inhibitors for cancer therapy

Journal of Hematology and Oncology

Volumn 3, Issue , 2010, Pages

  Frémin, Christophe ^a   Meloche, Sylvain ^a  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; AS 703026; AZD 8330; CAPECITABINE; EVEROLIMUS; GDC 0973; GSK 1120212; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; OXALIPLATIN; PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; RDEA 119; RO 09 2210; RO 4927350; RO 4987655; RO 5068760; RO 5126766; SORAFENIB; TAK 733; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MAP2K1 PROTEIN, HUMAN; MAP2K2 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROTEIN KINASE INHIBITOR;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLURRED VISION; BREAST CANCER; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL EVALUATION; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG STRUCTURE; DRUG WITHDRAWAL; HUMAN; LEUKEMIA; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; NAUSEA; NEUROTOXICITY; NONHUMAN; PANCREAS CANCER; RASH; REVIEW; SINGLE DRUG DOSE; SKIN CANCER; SOLID TUMOR; TREATMENT FAILURE; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; VOMITING; ANIMAL; BIOLOGICAL MODEL; DRUG ANTAGONISM; METHODOLOGY; NEOPLASM; RESEARCH;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MODELS, BIOLOGICAL; NEOPLASMS; PROTEIN KINASE INHIBITORS; RESEARCH;

EID: 77949464718     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-3-8     Document Type: Review

References (105)

1. The hallmarks of cancer. D Hanahan RA Weinberg, Cell 2000 100 57 70 10.1016/S0092-8674(00)81683-9 10647931
2. Characterization of insulin-stimulated microtubule-associated protein kinase. Rapid isolation and stabilization of a novel serine/threonine kinase from 3T3-L1 cells. LB Ray TW Sturgill, J Biol Chem 1988 263 12721 12727 2842341
3. Differential regulation and properties of MAPKs. M Raman W Chen MH Cobb, Oncogene 2007 26 3100 3112 10.1038/sj.onc.1210392 17496909
4. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. S Yoon R Seger, Growth Factors 2006 24 21 44 10.1080/02699050500284218 16393692
5. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. G Pearson F Robinson T Beers Gibson BE Xu M Karandikar K Berman MH Cobb, Endocr Rev 2001 22 153 183 10.1210/er.22.2.153 11294822
6. Mechanism of p38 MAP kinase activation in vivo. D Brancho N Tanaka A Jaeschke JJ Ventura N Kelkar Y Tanaka M Kyuuma T Takeshita RA Flavell RJ Davis, Genes Dev 2003 17 1969 1978 10.1101/gad.1107303 12893778
7. SEK1 deficiency reveals mitogen-activated protein kinase cascade crossregulation and leads to abnormal hepatogenesis. S Ganiatsas L Kwee Y Fujiwara A Perkins T Ikeda MA Labow LI Zon, Proc Natl Acad Sci USA 1998 95 6881 6886 10.1073/pnas.95.12.6881 9618507
8. Cytoplasmic localization of mitogen-activated protein kinase kinase directed by its NH2-terminal, leucine-rich short amino acid sequence, which acts as a nuclear export signal. M Fukuda I Gotoh Y Gotoh E Nishida, J Biol Chem 1996 271 20024 20028 10.1074/jbc.271.33.20024 8702720
9. Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor gamma. E Burgermeister D Chuderland T Hanoch M Meyer M Liscovitch R Seger, Mol Cell Biol 2007 27 803 817 10.1128/MCB.00601-06 17101779
10. Rac-PAK signaling stimulates extracellular signal-regulated kinase (ERK) activation by regulating formation of MEK1-ERK complexes. ST Eblen JK Slack MJ Weber AD Catling, Mol Cell Biol 2002 22 6023 6033 10.1128/MCB.22.17.6023-6033. 2002 12167697
11. Selective activation of MEK1 but not MEK2 by A-Raf from epidermal growth factor-stimulated Hela cells. X Wu SJ Noh G Zhou JE Dixon KL Guan, J Biol Chem 1996 271 3265 3271 10.1074/jbc.271.6.3265 8621729
12. Differential regulation of mitogen-activated protein/ERK kinase (MEK)1 and MEK2 and activation by a Ras-independent mechanism. S Xu S Khoo A Dang S Witt V Do E Zhen EM Schaefer MH Cobb, Mol Endocrinol 1997 11 1618 1625 10.1210/me.11.11.1618 9328344
13. A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal. F Catalanotti G Reyes V Jesenberger G Galabova-Kovacs R de Matos Simoes O Carugo M Baccarini, Nat Struct Mol Biol 2009 16 294 303 10.1038/nsmb.1564 19219045
14. Mek1 alters epidermal growth and differentiation. FA Scholl PA Dumesic PA Khavari, Cancer Res 2004 64 6035 6040 10.1158/0008-5472.CAN-04-0017 15342384
15. Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors. L Voisin C Julien S Duhamel K Gopalbhai I Claveau MK Saba-El-Leil IG Rodrigue-Gervais L Gaboury D Lamarre M Basik, et al. BMC Cancer 2008 8 337 10.1186/1471-2407-8-337 19014680
16. Mek1/2 gene dosage determines tissue response to oncogenic Ras signaling in the skin. FA Scholl PA Dumesic DI Barragan J Charron PA Khavari, Oncogene 2009 28 1485 1495 10.1038/onc.2008.459 19198628
17. Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway. N Mody J Leitch C Armstrong J Dixon P Cohen, FEBS Lett 2001 502 21 24 10.1016/S0014-5793(01)02651-5 11478941
18. Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. S Kamakura T Moriguchi E Nishida, J Biol Chem 1999 274 26563 26571 10.1074/jbc.274.37.26563 10473620
19. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. JF Ohren H Chen A Pavlovsky C Whitehead E Zhang P Kuffa C Yan P McConnell C Spessard C Banotai, et al. Nat Struct Mol Biol 2004 11 1192 1197 10.1038/nsmb859 15543157
20. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. S Meloche J Pouyssegur, Oncogene 2007 26 3227 3239 10.1038/sj.onc.1210414 17496918
21. Biphasic and synergistic activation of p44mapk (ERK1) by growth factors: correlation between late phase activation and mitogenicity. S Meloche K Seuwen G Pages J Pouyssegur, Mol Endocrinol 1992 6 845 854 10.1210/me.6.5.845 1603090
22. Growth-factor-dependent mitogenesis requires two distinct phases of signalling. SM Jones A Kazlauskas, Nat Cell Biol 2001 3 165 172 10.1038/35055073 11175749
23. Continuous ERK activation downregulates antiproliferative genes throughout G1 phase to allow cell-cycle progression. T Yamamoto M Ebisuya F Ashida K Okamoto S Yonehara E Nishida, Curr Biol 2006 16 1171 1182 10.1016/j.cub.2006.04.044 16782007
24. Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. G Pages P Lenormand G L'Allemain JC Chambard S Meloche J Pouyssegur, Proc Natl Acad Sci USA 1993 90 8319 8323 10.1073/pnas.90.18.8319 8397401
25. The MAP kinase pathway is required for entry into mitosis and cell survival. X Liu S Yan T Zhou Y Terada RL Erikson, Oncogene 2004 23 763 776 10.1038/sj.onc.1207188 14737111
26. ERK2 but not ERK1 plays a key role in hepatocyte replication: An RNAi-mediated ERK2 knockdown approach in wild-type and ERK1 null hepatocytes. C Fremin F Ezan P Boisselier A Bessard G Pages J Pouyssegur G Baffet, Hepatology 2007 45 1035 1045 10.1002/hep.21551 17393467
27. Single and combined ERK1/ERK2 silencing reveals their positive contribution to growth signaling depending on their expression levels. R Lefloch J Pouyssegur P Lenormand, Mol Cell Biol 2007 17967895
28. A synthetic inhibitor of the mitogen-activated protein kinase cascade. DT Dudley L Pang SJ Decker AJ Bridges AR Saltiel, Proc Natl Acad Sci USA 1995 92 7686 7689 10.1073/pnas.92.17.7686 7644477
29. Inhibition of mitogen-activated protein kinase kinase blocks T cell proliferation but does not induce or prevent anergy. DR DeSilva EA Jones MF Favata BD Jaffee RL Magolda JM Trzaskos PA Scherle, J Immunol 1998 160 4175 4181 9574517
30. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. JS Sebolt-Leopold DT Dudley R Herrera K Van Becelaere A Wiland RC Gowan H Tecle SD Barrett A Bridges S Przybranowski, et al. Nat Med 1999 5 810 816 10.1038/10533 10395327
31. Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts. A Brunet G Pages J Pouyssegur, Oncogene 1994 9 3379 3387 7936666
32. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. S Cowley H Paterson P Kemp CJ Marshall, Cell 1994 77 841 852 10.1016/0092-8674(94)90133-3 7911739
33. Overexpression of mitogen-activated protein kinase kinase (MAPKK) and its mutants in NIH 3T3 cells. Evidence that MAPKK involvement in cellular proliferation is regulated by phosphorylation of serine residues in its kinase subdomains VII and VIII. R Seger D Seger AA Reszka ES Munar H Eldar-Finkelman G Dobrowolska AM Jensen JS Campbell EH Fischer EG Krebs, J Biol Chem 1994 269 25699 25709 7929275
34. Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. G Pages S Guerin D Grall F Bonino A Smith F Anjuere P Auberger J Pouyssegur, Science 1999 286 1374 1377 10.1126/science.286.5443.1374 10558995
35. An essential function of the mitogen-activated protein kinase Erk2 in mouse trophoblast development. MK Saba-El-Leil FD Vella B Vernay L Voisin L Chen N Labrecque SL Ang S Meloche, EMBO Rep 2003 4 964 968 10.1038/sj.embor.embor939 14502223
36. Deletion of ERK2 mitogen-activated protein kinase identifies its key roles in cortical neurogenesis and cognitive function. IS Samuels JC Karlo AN Faruzzi K Pickering K Herrup JD Sweatt SC Saitta GE Landreth, J Neurosci 2008 28 6983 6995 10.1523/JNEUROSCI.0679-08.2008 18596172
37. The Erk2 MAPK regulates CD8 T cell proliferation and survival. WN D'Souza CF Chang AM Fischer M Li SM Hedrick, J Immunol 2008 181 7617 7629 19017950
38. Integrating the MAP kinase signal into the G1 phase cell cycle machinery. K Roovers RK Assoian, Bioessays 2000 22 818 826 10.1002/1521-1878(200009)22: 9<818::AID-BIES73.0.CO;2-6 10944584
39. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. JN Lavoie G L'Allemain A Brunet R Muller J Pouyssegur, J Biol Chem 1996 271 20608 20616 10.1074/jbc.271.34.20608 8702807
40. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. R Sears F Nuckolls E Haura Y Taya K Tamai JR Nevins, Genes Dev 2000 14 2501 2514 10.1101/gad.836800 11018017
41. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. JY Yang CS Zong W Xia H Yamaguchi Q Ding X Xie JY Lang CC Lai CJ Chang WC Huang, et al. Nat Cell Biol 2008 10 138 148 10.1038/ncb1676 18204439
42. Extracellular signal-regulated kinase 2-dependent phosphorylation induces cytoplasmic localization and degradation of p21Cip1. CY Hwang C Lee KS Kwon, Mol Cell Biol 2009 29 3379 3389 10.1128/MCB.01758-08 19364816
43. ERK implication in cell cycle regulation. JC Chambard R Lefloch J Pouyssegur P Lenormand, Biochim Biophys Acta 2007 1773 1299 1310 10.1016/j.bbamcr.2006.11.010 17188374
44. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. PP Roux BA Ballif R Anjum SP Gygi J Blenis, Proc Natl Acad Sci USA 2004 101 13489 13494 10.1073/pnas.0405659101 15342917
45. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. L Ma Z Chen H Erdjument-Bromage P Tempst PP Pandolfi, Cell 2005 121 179 193 10.1016/j.cell.2005.02.031 15851026
46. Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. BA Ballif J Blenis, Cell Growth Differ 2001 12 397 408 11504705
47. Tumour cell survival signalling by the ERK1/2 pathway. K Balmanno SJ Cook, Cell Death Differ 2009 16 368 377 10.1038/cdd.2008.148 18846109
48. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Z Xia M Dickens J Raingeaud RJ Davis ME Greenberg, Science 1995 270 1326 1331 10.1126/science.270.5240.1326 7481820
49. Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways. M Parrizas AR Saltiel D LeRoith, J Biol Chem 1997 272 154 161 10.1074/jbc.272.1. 154 8995241
50. B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. P Erhardt EJ Schremser GM Cooper, Mol Cell Biol 1999 19 5308 5315 10409722
51. The p42/p44 MAP kinase pathway prevents apoptosis induced by anchorage and serum removal. M Le Gall JC Chambard JP Breittmayer D Grall J Pouyssegur E Van Obberghen-Schilling, Mol Biol Cell 2000 11 1103 1112 10712523
52. MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. DJ Lips OF Bueno BJ Wilkins NH Purcell RA Kaiser JN Lorenz L Voisin MK Saba-El-Leil S Meloche J Pouyssegur, et al. Circulation 2004 109 1938 1941 10.1161/01.CIR.0000127126.73759.23 15096454
53. Mek1/2 MAPK kinases are essential for Mammalian development, homeostasis, and Raf-induced hyperplasia. FA Scholl PA Dumesic DI Barragan K Harada V Bissonauth J Charron PA Khavari, Dev Cell 2007 12 615 629 10.1016/j.devcel.2007. 03.009 17419998
54. Signaling through the epidermal growth factor receptor during the development of malignancy. JR Grandis JC Sok, Pharmacol Ther 2004 102 37 46 10.1016/j.pharmthera.2004.01.002 15056497
55. ERBB receptors and cancer: the complexity of targeted inhibitors. NE Hynes HA Lane, Nat Rev Cancer 2005 5 341 354 10.1038/nrc1609 15864276
56. Hyperactive Ras in developmental disorders and cancer. S Schubbert K Shannon G Bollag, Nat Rev Cancer 2007 7 295 308 10.1038/nrc2109 17384584
57. Mutations of the BRAF gene in human cancer. H Davies GR Bignell C Cox P Stephens S Edkins S Clegg J Teague H Woffendin MJ Garnett W Bottomley, et al. Nature 2002 417 949 954 10.1038/nature00766 12068308
58. Guilty as charged: B-RAF is a human oncogene. MJ Garnett R Marais, Cancer Cell 2004 6 313 319 10.1016/j.ccr.2004.09.022 15488754
59. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. JL Marks Y Gong D Chitale B Golas MD McLellan Y Kasai L Ding ER Mardis RK Wilson D Solit, et al. Cancer Res 2008 68 5524 5528 10.1158/0008-5472.CAN-08-0099 18632602
60. MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas. AK Murugan J Dong J Xie M Xing, Cell Cycle 2009 8 2122 2124 19411838
61. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. R Hoshino Y Chatani T Yamori T Tsuruo H Oka O Yoshida Y Shimada S Ari-i H Wada J Fujimoto, et al. Oncogene 1999 18 813 822 10.1038/sj.onc.1202367 9989833
62. Targeting the mitogen-activated protein kinase cascade to treat cancer. JS Sebolt-Leopold R Herrera, Nat Rev Cancer 2004 4 937 947 10.1038/nrc1503 15573115
63. Transformation of mammalian cells by constitutively active MAP kinase kinase. SJ Mansour WT Matten AS Hermann JM Candia S Rong K Fukasawa GF Vande Woude NG Ahn, Science 1994 265 966 970 10.1126/science.8052857 8052857
64. MEK1 signaling mediates transformation and metastasis of EpH4 mammary epithelial cells independent of an epithelial to mesenchymal transition. J Pinkas P Leder, Cancer Res 2002 62 4781 4790 12183438
65. Raf kinases: function, regulation and role in human cancer. DT Leicht V Balan A Kaplun V Singh-Gupta L Kaplun M Dobson G Tzivion, Biochim Biophys Acta 2007 1773 1196 1212 10.1016/j.bbamcr.2007.05.001 17555829
66. Expression of activated MEK1 in differentiating epidermal cells is sufficient to generate hyperproliferative and inflammatory skin lesions. RM Hobbs V Silva-Vargas R Groves FM Watt, J Invest Dermatol 2004 123 503 515 10.1111/j.0022-202X.2004.23225.x 15304090
67. Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice. VK Goel N Ibrahim G Jiang M Singhal S Fee T Flotte S Westmoreland FS Haluska PW Hinds FG Haluska, Oncogene 2009 28 2289 2298 10.1038/onc.2009.95 19398955
68. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. JA Knauf X Ma EP Smith L Zhang N Mitsutake XH Liao S Refetoff YE Nikiforov JA Fagin, Cancer Res 2005 65 4238 4245 10.1158/0008-5472.CAN-05-0047 15899815
69. BRAF activation initiates but does not maintain invasive prostate adenocarcinoma. JH Jeong Z Wang AS Guimaraes X Ouyang JL Figueiredo Z Ding S Jiang I Guney GH Kang E Shin, et al. PLoS One 2008 3 3949 10.1371/journal.pone. 0003949 19079609
70. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. H Ji Z Wang SA Perera D Li MC Liang S Zaghlul K McNamara L Chen M Albert Y Sun, et al. Cancer Res 2007 67 4933 4939 10.1158/0008-5472.CAN-06-4592 17510423
71. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. M Milella SM Kornblau Z Estrov BZ Carter H Lapillonne D Harris M Konopleva S Zhao E Estey M Andreeff, J Clin Invest 2001 108 851 859 11560954
72. BRAF mutation predicts sensitivity to MEK inhibition. DB Solit LA Garraway CA Pratilas A Sawai G Getz A Basso Q Ye JM Lobo Y She I Osman, et al. Nature 2006 439 358 362 10.1038/nature04304 16273091
73. Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade. EA Collisson A De H Suzuki SS Gambhir MS Kolodney, Cancer Res 2003 63 5669 5673 14522881
74. Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure. BW Kramer R Gotz UR Rapp, BMC Cancer 2004 4 24 10.1186/1471-2407-4-24 15171791
75. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. DR Alessi A Cuenda P Cohen DT Dudley AR Saltiel, J Biol Chem 1995 270 27489 27494 10.1074/jbc.270.46.27489 7499206
76. Inhibition of growth factor-induced protein synthesis by a selective MEK inhibitor in aortic smooth muscle cells. MJ Servant E Giasson S Meloche, J Biol Chem 1996 271 16047 16052 10.1074/jbc.271.27.16047 8663242
77. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. MF Favata KY Horiuchi EJ Manos AJ Daulerio DA Stradley WS Feeser DE Van Dyk WJ Pitts RA Earl F Hobbs, et al. J Biol Chem 1998 273 18623 18632 10.1074/jbc.273.29.18623 9660836
78. Ro 09-2210 exhibits potent anti-proliferative effects on activated T cells by selectively blocking MKK activity. DH Williams SE Wilkinson T Purton A Lamont H Flotow EJ Murray, Biochemistry 1998 37 9579 9585 10.1021/bi972914c 9649341
79. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. PM Lorusso AA Adjei M Varterasian S Gadgeel J Reid DY Mitchell L Hanson P DeLuca L Bruzek J Piens, et al. J Clin Oncol 2005 23 5281 5293 10.1200/JCO.2005.14.415 16009947
80. Multicenter phase II study of the oral MEK inhibitor, CI- in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Rinehart AA Adjei PM Lorusso D Waterhouse JR Hecht RB Natale O Hamid M Varterasian P Asbury EP Kaldjian, et al. J Clin Oncol 1040 22 4456 4462 10.1200/JCO.2004.01.185
81. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. SD Barrett AJ Bridges DT Dudley AR Saltiel JH Fergus CM Flamme AM Delaney M Kaufman S LePage WR Leopold, et al. Bioorg Med Chem Lett 2008 18 6501 6504 10.1016/j.bmcl.2008.10.054 18952427
82. A phase 1-2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer. P Lorusso S Krishnamurthi JR Rinehart L Nabell G Croghan M Varterasian SS Sadis SS Menon J Leopold MB Meyer, J Clin Oncol (abstract) 2005 23 3011
83. Pharmacokinetics (PK) and pharmacodynamics (PD) of PD0325901, a second generation MEK inhibitor after multiple oral doses of PD0325901 to advanced cancer patients. SS Menon LR Whitfield S Sadis MB Meyer J Leopold PM Lorusso S Krishnamurthi JR Rinehart L Nabell G Croghan, J Clin Oncol (abstract) 2005 23 3066
84. Clinical experience of MEK inhibitors in cancer therapy. D Wang SA Boerner JD Winkler PM LoRusso, Biochim Biophys Acta 2007 1773 1248 1255 10.1016/j.bbamcr.2006.11.009 17194493
85. Clinical aspects of a phase I study of PD032 a selective oral MEK inhibitor, in patients with advanced cancer. P Lorusso S Krishnamurthi J Rinehart L Nabell G Croghan P Chapman P Selaru S Kim A Ricart K Wliner, Mol Cancer Ther (abstract B113) 5901 6 3646s
86. Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor. TC Yeh V Marsh BA Bernat J Ballard H Colwell RJ Evans J Parry D Smith BJ Brandhuber S Gross, et al. Clin Cancer Res 2007 13 1576 1583 10.1158/1078-0432.CCR-06-1150 17332304
87. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. BR Davies A Logie JS McKay P Martin S Steele R Jenkins M Cockerill S Cartlidge PD Smith, Mol Cancer Ther 2007 6 2209 2219 10.1158/1535-7163.MCT-07-0231 17699718
88. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. H Huynh KC Soo PK Chow E Tran, Mol Cancer Ther 2007 6 138 146 10.1158/1535-7163.MCT-06-0436 17237274
89. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. NK Haass K Sproesser TK Nguyen R Contractor CA Medina KL Nathanson M Herlyn KS Smalley, Clin Cancer Res 2008 14 230 239 10.1158/1078-0432.CCR-07-1440 18172275
90. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. AA Adjei RB Cohen W Franklin C Morris D Wilson JR Molina LJ Hanson L Gore L Chow S Leong, et al. J Clin Oncol 2008 26 2139 2146 10.1200/JCO.2007.14.4956 18390968
91. AZD6244 (ARRY-142886) vs Temozolomide in Patients With Advanced Melanoma: an Open-Label, Randomized, Multicenter, Phase II Study. R Drummer C Robert P Chapman J Sosman M Middleton L Bastholt K Kemsley M Cantarini C Morris J Kirkwood, J Clin Oncol (abstract) 2008 26 9033
92. Efficacy and safety of AZD6244 (ARRY-142886) as second/third-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC). V Tzekova C Cebotaru TE Ciuleanu D Damjanov V Ganchev V Kanarev PJ Stella N Sanders G Pover JD Hainsworth, J Clin Oncol (abstract) 2008 26 8029
93. AZD6244 (ARRY-142886) Versus Capecitabine in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Chemotherapy. I Lang A Adenis K Boer P Escudero T Kim M Valladares N Sanders G Pover JY Douillard, J Clin Oncol (abstract) 2008 26 4114
94. A phase II study of AZD6244 in advanced or metastatic hepatocellular carcinoma. BH O'Neil LW Williams-Goff J Kauh T Bekaii-Saab JR Strosberg R Lee AM Deal D Sullivan SM Sebti, J Clin Oncol (abstract) 2009 27 15574
95. XL518, a potent, selective orally bioavailable MEK1 inhibitor, down-regulates the Ras/Raf/MEK/ERK pathway in vivo, resulting in tumor growth inhibition and regression in preclinical models. S Johnston, 19th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2007 Abstract C209
96. A phase 1 dose-escalation study of XL518, a potent MEK inhibitor administered orally daily to subjects with solid tumors. LS Rosen P Galatin JM Fehling I Laux M Dinolfo J Frye D Laird BI Sikic, J Clin Oncol (abstract) 2008 26 14585
97. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. C Iverson G Larson C Lai LT Yeh C Dadson P Weingarten T Appleby T Vo A Maderna JM Vernier, et al. Cancer Res 2009 69 6839 6847 10.1158/0008-5472.CAN-09-0679 19706763
98. A three-part, phase I, dose-escalation study of GSK1120212, a potent MEK inhibitor, administred orally with solid tumors or lymphoma. D Thompson K Flaherty W Messersmith K Harlacker S Nallapareddy C Vincent D DeMarini D Cox V O'Neill H Burris, J Clin Oncol (abstract) 2009 27 14584
99. Preclinical in vivo evaluation of efficacy, pharmacokinetics, and pharmacodynamics of a novel MEK1/2 kinase inhibitor RO5068760 in multiple tumor models. S Daouti B Higgins K Kolinsky K Packman H Wang C Rizzo J Moliterni N Huby N Fotouhi M Liu, et al. Mol Cancer Ther 2010 9 134 144 10.1158/1535-7163. MCT-09-0601 20053779
100. Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy. S Daouti H Wang WH Li B Higgins K Kolinsky K Packman A Specian Jr N Kong N Huby Y Wen, et al. Cancer Res 2009 69 1924 1932 10.1158/0008-5472.CAN-08-2627 19244124
101. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. S Wilhelm C Carter M Lynch T Lowinger J Dumas RA Smith B Schwartz R Simantov S Kelley, Nat Rev Drug Discov 2006 5 835 844 10.1038/nrd2130 17016424
102. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. S Wee Z Jagani KX Xiang A Loo M Dorsch YM Yao WR Sellers C Lengauer F Stegmeier, Cancer Res 2009 69 4286 4293 10.1158/0008-5472.CAN-08-4765 19401449
103. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. JA Engelman L Chen X Tan K Crosby AR Guimaraes R Upadhyay M Maira K McNamara SA Perera Y Song, et al. Nat Med 2008 14 1351 1356 10.1038/nm.1890 19029981
104. Nature Journal. http://www.nature.com/news/2009/090602/full/news.2009. 536.html
105. MEK1 mutations confer resistance to MEK and B-RAF inhibition. CM Emery KG Vijayendran MC Zipser AM Sawyer L Niu JJ Kim C Hatton R Chopra PA Oberholzer MB Karpova, et al. Proc Natl Acad Sci USA 2009 106 20411 20416 10.1073/pnas.0905833106 19915144